PlumX Metrics
Embed PlumX Metrics

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Fertility and Sterility, ISSN: 0015-0282, Vol: 83, Issue: 3, Page: 804-807
2005
  • 13
    Citations
  • 0
    Usage
  • 16
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

This study compared the cost and effectiveness of highly purified, human-derived follicle-stimulating hormone (FSH) (Bravelle ® ) to recombinant FSH (Follistim ® ) using Markov modeling and Monte Carlo simulation. One IVF treatment cycle resulted in costs of $11,584 ± $211 for human-derived FSH and $12,762 ± $170 for recombinant FSH, while three treatment cycles, holding the transition probabilities of the first cycle constant for the next two cycles, resulted in costs of $22,712 ± $1,107 for human-derived FSH and $24,935 ± $1,205 for recombinant FSH.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know